Article Detail - JE Part B
MolDX: Plasma-Based Genomic Profiling in Solid Tumors L39230 Final LCD - Effective December 26, 2022
This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L39230
LCD Title: MolDX: Plasma-Based Genomic Profiling in Solid Tumors
Effective Date: December 26, 2022
Summary of LCD: This is a limited coverage policy for next-generation sequencing (NGS) assays performed on solid tumor cell-free deoxyribonucleic acid (DNA) in plasma, from here on called “liquid biopsies.”
Visit the Proposed LCDs webpage to access this LCD.
Last Updated Mon, 14 Nov 2022 21:34:43 +0000